Additionally, alternative myostatin-targeting approaches, such as the myostatin-blocking peptide PINTA 745, have demonstrated similar benefits, increasing muscle mass and improving function in models of stroke and chronic kidney disease (200, 201). Here, MSTN is linked to chronic kidney disease.